UBS AM’s BioAtla BCAB Stock Holding History

UBS AM’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-173	Closed	-$254K	–	2845
2021 Q3	$254K	Buy	+173	New	+$337K	﹤0.01%	2651

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

UBS AM's BCAB Position: Q4 2021 in Review

UBS AM sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 173 shares — an estimated $254K sold.

UBS AM first reported a position in BCAB in Q3 2021 and held it in 1 quarter. The position peaked at $254K in Q3 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

UBS AM reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
UBS AM sold 173 BioAtla shares in Q4 2021, an estimated $254K.
UBS AM first reported a position in BioAtla in Q3 2021 and held it in 1 quarter.
UBS AM's BioAtla position peaked at $254K in Q3 2021.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.